Related references
Note: Only part of the references are listed.Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
Martin J. Schlumberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)
R. Salgia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
New therapeutic approaches to treat medullary thyroid carcinoma
Martin Schlumberger et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2008)
Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension
Hassane Izzedine et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells
Nagako Akeno-Stuart et al.
CANCER RESEARCH (2007)
What is the most cost-effective population-based cancer screening program for Chinese women?
Pauline P. S. Woo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Toxicities of antiangiogenic therapy in non-small-cell lung cancer
Roy S. Herbst
CLINICAL LUNG CANCER (2006)
Prognosis of medullary thyroid carcinoma - Demographic, clinical, and pathologic predictors of survival in 1252 cases
Sanziana Roman et al.
CANCER (2006)
Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer
M Santoro et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2006)
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
SN Holden et al.
ANNALS OF ONCOLOGY (2005)
RET proto-oncogene:: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors
MA Kouvaraki et al.
THYROID (2005)
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma
M Vidal et al.
CANCER RESEARCH (2005)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
